发明授权
US06953857B2 Oxybenzamide derivatives useful for inhibiting factor Xa or viia
失效
用于抑制因子Xa或vii的氧苯甲酰胺衍生物
- 专利标题: Oxybenzamide derivatives useful for inhibiting factor Xa or viia
- 专利标题(中): 用于抑制因子Xa或vii的氧苯甲酰胺衍生物
-
申请号: US10023933申请日: 2001-12-21
-
公开(公告)号: US06953857B2公开(公告)日: 2005-10-11
- 发明人: Marc Nazaré , David William Will , Anuschirwan Peyman , Hans Matter , Gerhard Zoller , Uwe Gerlach
- 申请人: Marc Nazaré , David William Will , Anuschirwan Peyman , Hans Matter , Gerhard Zoller , Uwe Gerlach
- 申请人地址: DE Frankfurt am Main
- 专利权人: Aventis Pharma Deutschland GmbH
- 当前专利权人: Aventis Pharma Deutschland GmbH
- 当前专利权人地址: DE Frankfurt am Main
- 代理商 Joseph D. Rossi
- 优先权: EP00128477 20001223
- 主分类号: C07D243/08
- IPC分类号: C07D243/08 ; A61K31/166 ; A61K31/167 ; A61K31/18 ; A61K31/277 ; A61K31/38 ; A61K31/4184 ; A61K31/422 ; A61K31/435 ; A61K31/4355 ; A61K31/437 ; A61K31/44 ; A61K31/4418 ; A61K31/4439 ; A61K31/445 ; A61K31/4453 ; A61K31/4465 ; A61K31/4468 ; A61K31/451 ; A61K31/4525 ; A61K31/453 ; A61K31/4535 ; A61K31/454 ; A61K31/4545 ; A61K31/4709 ; A61K31/495 ; A61K31/496 ; A61K31/4965 ; A61K31/497 ; A61K31/505 ; A61K31/506 ; A61K31/551 ; A61K31/635 ; A61P7/00 ; A61P7/02 ; A61P7/04 ; A61P9/00 ; A61P9/08 ; A61P9/10 ; A61P11/00 ; A61P29/00 ; A61P43/00 ; C07C235/50 ; C07C237/42 ; C07C255/60 ; C07C311/46 ; C07C311/51 ; C07D211/26 ; C07D211/58 ; C07D211/96 ; C07D213/30 ; C07D213/38 ; C07D213/40 ; C07D213/64 ; C07D213/74 ; C07D213/89 ; C07D235/06 ; C07D235/08 ; C07D239/42 ; C07D239/69 ; C07D241/12 ; C07D295/12 ; C07D295/13 ; C07D295/18 ; C07D295/192 ; C07D317/58 ; C07D333/16 ; C07D333/58 ; C07D401/00 ; C07D401/04 ; C07D401/06 ; C07D401/12 ; C07D401/14 ; C07D405/04 ; C07D405/08 ; C07D405/12 ; C07D405/14 ; C07D409/12 ; C07D409/14 ; C07D413/04 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D491/04 ; C07D491/048 ; C07D211/06
摘要:
The present invention relates to compounds comprising the following formula: R0—Q—X—Q′—W—U—V—G—M (I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
公开/授权文献
信息查询